Ethical aspects of malaria control and research

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Jamrozik, Euzebiusz ^a,b   De La Fuente Núñez, Vânia ^b   Reis, Andreas ^b   Ringwald, Pascal ^b   Selgelid, Michael J ^a  

^a MONASH UNIVERSITY   (Australia)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; MALARIA VACCINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ANTIMALARIAL DRUG RESISTANCE; BLOOD DONOR; BLOOD TRANSFUSION; CLIMATE CHANGE; COMBINATION CHEMOTHERAPY; DISEASE ERADICATION; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HUMAN; MALARIA; MALARIA CONTROL; MANDATORY TESTING; MEDICAL ETHICS; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW; TRANSGENIC ORGANISM; COMMUNICABLE DISEASE CONTROL; ETHICS; GLOBAL HEALTH; HEALTH CARE DELIVERY; PROCEDURES;

ANTIMALARIALS; BIOMEDICAL RESEARCH; COMMUNICABLE DISEASE CONTROL; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALARIA;

EID: 84951745051     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-1042-3     Document Type: Review

References (61)

1. WHO. World Malaria Report 2012. Geneva: World Health Organization; 2012.
2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379:413-31.
3. WHO. World Malaria Report 2013. Geneva: World Health Organization; 2013.
4. Spielman A. Ethical dilemmas in malaria control. J Vector Ecol. 2006;31:1-8.
5. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272-80.
6. Selgelid MJ, Kelly PM, Sleigh A. Ethical challenges in TB control in the era of XDR-TB. Int J Tuberc Lung Dis. 2008;12:231-5.
7. Selgelid MJ. Ethics, tuberculosis and globalization. Public Health Ethics. 2008;1:10-20.
8. Sweeney P, Gardner LI, Buchacz K, Garland PM, Mugavero MJ, Bosshart JT, et al. Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection. Milbank Q. 2013;91:558-603.
9. Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415:680-5.
10. Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg. 2001;64:85-96.
11. Selgelid MJ. Improving global health: counting reasons why. Dev World Bioeth. 2008;8:115-25.
12. Pogge T. Severe poverty as a violation of negative duties. Eth Int Aff. 2005;19:55-83.
13. Gardiner SM. Ethics and global climate change. Ethics. 2004;114:555-600.
14. Gething PW, Smith DL, Patil AP, Tatem AJ, Snow RW, Hay SI. Climate change and the global malaria recession. Nature. 2010;465:342-5.
15. Reiter P. From Shakespeare to Defoe: malaria in England in the Little Ice Age. Emerg Infect Dis. 2000;6:1-11.
16. Hay SI, Cox J, Rogers DJ, Randolph SE, Stern DI, Shanks GD, et al. Climate change and the resurgence of malaria in the East African highlands. Nature. 2002;415:905-9.
17. Martens P, Kovats R, Nijhof S, De Vries P, Livermore M, Bradley D, et al. Climate change and future populations at risk of malaria. Glob Environ Change. 1999;9:S89-107.
18. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev. 2004;2:CD000363.
19. Who GMP. WHO recommendations for achieving universal coverage with long-lasting insecticidal nets in malaria control. Geneva: World Health Organization; 2013.
20. Curtis C, Maxwell C, Lemnge M, Kilama WL, Steketee RW, Hawley WA, et al. Scaling-up coverage with insecticide-treated nets against malaria in Africa: who should pay? Lancet Infect Dis. 2003;3:304-7.
21. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, et al. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J. 2009;8:22.
22. Newton PN, Green MD, Fernández FM, Day NPJ, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6:602-13.
23. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 2001;17:593-7.
24. Parker MJ. Moral and scientific boundaries: research ethics on the Thai-Burma border. J Med Ethics. 2012;38:559-60.
25. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med. 2013;10:e1001398.
26. Huerga H, Lopez-Velez R. Imported malaria in immigrant and travelling children in Madrid. Eur J Clin Microbiol Infect Dis. 2001;20:591-3.
27. Tatarsky A, Aboobakar S, Cohen JM, Gopee N, Bheecarry A, Moonasar D, et al. Preventing the reintroduction of malaria in Mauritius: a programmatic and financial assessment. PLoS One. 2011;6:e23832.
28. Wickramage K, Galappaththy GNL, Dayarathne D, Peiris SL, Basnayake RN, Mosca D, et al. Irregular migration as a potential source of malaria reintroduction in Sri Lanka and use of malaria rapid diagnostic tests at point-of-entry screening. Case Rep Med. 2013;2013:465906.
29. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415-21.
30. Wickramage K, Premaratne RG, Peiris SL, Mosca D. High attack rate for malaria through irregular migration routes to a country on verge of elimination. Malar J. 2013;12:276.
31. Smith C, Whittaker M. Beyond mobile populations: a critical review of the literature on malaria and population mobility and suggestions for future directions. Malar J. 2014;13(10):1186.
32. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;12:CD008846.
33. King KF, Kolopack P, Merritt MW, Lavery JV. Community engagement and the human infrastructure of global health research. BMC Medical Ethics. 2014;15:84.
34. Baird JK, Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011;27:11-6.
35. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14:130-9.
36. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112.
37. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.
38. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508-34.
39. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang. 2006;90:77-84.
40. Maselli LM, Levy D, Laporta GZ, Monteiro AM, Fukuya LA, Ferreira-da-Cruz MF, et al. Detection of Plasmodium falciparum and Plasmodium vivax subclinical infection in non-endemic region: implications for blood transfusion and malaria epidemiology. Malar J. 2014;13:224.
41. Falade CO, Nash O, Akingbola TS, Michael OS, Olojede F, Ademowo OG. Blood banking in a malaria-endemic area: evaluating the problem posed by malarial parasitaemias. Ann Trop Med Parasitol. 2009;103:383-92.
42. Choudhury LP, Tetali S. Ethical challenges in voluntary blood donation in Kerala, India. J Med Ethics. 2007;33:140-2.
43. Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis. 2001;33:1028-33.
44. Manson P. Experimental proof of the mosquitomalaria theory. BMJ. 1900;2:949.
45. Miller FG. The Stateville penitentiary malaria experiments: a case study in retrospective ethical assessment. Perspect Biol Med. 2013;56:548-67.
46. Eckart WU, Vondra H. Malaria and World War II: German malaria experiments 1939-1945. Parassitologia. 2000;42:53-8.
47. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis. 1997;175:915-20.
48. Spring M, Polhemus M, Ockenhouse C. Controlled human malaria infection. J Infect Dis. 2014;209:S40-5.
49. Mamotte N, Wassenaar D, Koen J, Essack Z. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa. BMC Med Ethics. 2010;11:3.
50. Ndebele P, Musesengwa R. View point: ethical dilemmas in malaria vector research in Africa: making the difficult choice between mosquito, science and humans. Malawi Med J. 2012;24:65-8.
51. Mathenge EM, Omweri GO, Irungu LW, Ndegwa PN, Walczak E, Smith TA, et al. Comparative field evaluation of the Mbita trap, the Centers for Disease Control light trap, and the human landing catch for sampling of malaria vectors in western Kenya. Am J Trop Med Hyg. 2004;70:33-7.
52. Mathenge EM, Misiani GO, Oulo DO, Irungu LW, Ndegwa PN. Comparative performance of the Mbita trap CDC light trap and the human landing catch in the sampling of Anopheles arabiensis, An. funestus and culicine species in a rice irrigation in western Kenya. Malar J. 2014;4:6.
53. Dawson A. Vaccination ethics. In: Dawson A editor. Public Health Ethics. Key concepts and issues in policy and practice. Cambridge: Cambridge University Press; 2011. 8:143-53.
54. Verweij M, Dawson A. Ethical principles for collective immunisation programmes. Vaccine. 2004;22:3122-6.
55. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685.
56. WHO. Expert consultation on the use of placebos in vaccine trials. Geneva: World Health Organization; 2013.
57. Alphey L, Beard CB, Billingsley P, Coetzee M, Crisanti A, Curtis C, et al. Malaria control with genetically manipulated insect vectors. Science. 2002;298:119-21.
58. Kilama WL. Health research ethics in malaria vector trials in Africa. Malar J. 2010;9(Suppl 3):S3.
59. Kilama WL. Health research ethics in public health: trials and implementation of malaria mosquito control strategies. Acta Trop. 2009;112(Suppl 1):S37-47.
60. Scott TW, Takken W, Knols BG, Boete C. The ecology of genetically modified mosquitoes. Science. 2002;298:117-9.
61. WHO, TDR. Guidance framework for testing of genetically modified mosquitoes. Geneva: World Health Organization; 2014.